Susquehanna Fundamental Investments LLC Purchases Shares of 10,355 ADC Therapeutics SA (NYSE:ADCT)

Susquehanna Fundamental Investments LLC acquired a new position in ADC Therapeutics SA (NYSE:ADCT) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,355 shares of the company’s stock, valued at approximately $33,000.

A number of other large investors also recently modified their holdings of the stock. Affinity Asset Advisors LLC bought a new position in shares of ADC Therapeutics during the second quarter valued at about $1,500,000. Bank of New York Mellon Corp bought a new position in shares of ADC Therapeutics during the 2nd quarter worth approximately $648,000. Sanibel Captiva Trust Company Inc. purchased a new position in shares of ADC Therapeutics in the 1st quarter worth approximately $462,000. Rhumbline Advisers bought a new position in shares of ADC Therapeutics in the second quarter valued at approximately $272,000. Finally, XTX Topco Ltd increased its position in shares of ADC Therapeutics by 129.0% during the second quarter. XTX Topco Ltd now owns 56,863 shares of the company’s stock valued at $180,000 after acquiring an additional 32,034 shares during the last quarter. Institutional investors own 41.10% of the company’s stock.

ADC Therapeutics Price Performance

NYSE:ADCT opened at $3.29 on Friday. The company has a market capitalization of $272.34 million, a P/E ratio of -1.20 and a beta of 1.58. The business has a fifty day simple moving average of $2.98 and a two-hundred day simple moving average of $3.58. ADC Therapeutics SA has a 1 year low of $0.36 and a 1 year high of $6.04.

ADC Therapeutics (NYSE:ADCT) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. The firm had revenue of $17.41 million during the quarter, compared to analysts’ expectations of $19.06 million. During the same period last year, the business posted ($0.58) EPS. As a group, analysts anticipate that ADC Therapeutics SA will post -1.69 earnings per share for the current year.

Analysts Set New Price Targets

ADCT has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of ADC Therapeutics in a research note on Thursday, August 8th. Royal Bank of Canada restated an “outperform” rating and set a $8.00 price target on shares of ADC Therapeutics in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.